{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T09:39:56Z","timestamp":1771234796091,"version":"3.50.1"},"reference-count":50,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2021,3,28]],"date-time":"2021-03-28T00:00:00Z","timestamp":1616889600000},"content-version":"unspecified","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,1,31]]},"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:p>Cancer immunotherapy based on the use of antibodies targeting the so-called checkpoint inhibitors, such as programmed cell death-1 receptor, its ligand, or CTLA-4, has shown durable clinical benefit and survival improvement in melanoma and other tumors. However, there are some special situations that could be a challenge for clinical management. Persons with chronic infections, such as HIV-1 or viral hepatitis, latent tuberculosis, or a history of solid organ transplantation, could be candidates for cancer immunotherapy, but their management requires a multidisciplinary approach. The Spanish Melanoma Group (GEM) panel in collaboration with experts in virology and immunology from different centers in Spain reviewed the literature and developed evidence-based guidelines for cancer immunotherapy management in patients with chronic infections and immunosuppression. These are the first clinical guidelines for cancer immunotherapy treatment in special challenging populations. Cancer immunotherapy in chronically infected or immunosuppressed patients is feasible but needs a multidisciplinary approach in order to decrease the risk of complications related to the coexistent comorbidities.<\/jats:p>","DOI":"10.1136\/jitc-2020-001664","type":"journal-article","created":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T11:10:25Z","timestamp":1617016225000},"page":"e001664","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3791-540X","authenticated-orcid":false,"given":"Maria","family":"Gonzalez-Cao","sequence":"first","affiliation":[{"name":"Translational Cancer Research Unit, Instituto Oncologico Dr Rosell, Dexeus University Hospital, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Puertolas","sequence":"additional","affiliation":[{"name":"Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Arag\u00f3n, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar","family":"Riveiro","sequence":"additional","affiliation":[{"name":"Liver Unit, Department of Internal Medicine, Vall d\u2019Hebron Hospital Universitari, Barcelona, Catalunya, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Mu\u00f1oz-Couselo","sequence":"additional","affiliation":[{"name":"Oncology Department, Vall d\u2019Hebron Hospital Universitari, Barcelona, Catalunya, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Ortiz","sequence":"additional","affiliation":[{"name":"Oncology Department, Vall d\u2019Hebron Hospital Universitari, Barcelona, Catalunya, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Paredes","sequence":"additional","affiliation":[{"name":"IrsiCaixa AIDS Research Institute, Badalona, Catalunya, Spain"},{"name":"Department of Infectious Diseases, Hospital Universitari Germans Trias i Pujol, Badalona, Catalunya, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Podzamczer","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Catalunya, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Luis","family":"Manzano","sequence":"additional","affiliation":[{"name":"Oncology Department, Hospital Germans Trias i Pujol, Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Molto","sequence":"additional","affiliation":[{"name":"IrsiCaixa AIDS Research Institute, Badalona, Catalunya, Spain"},{"name":"Department of Infectious Diseases, Hospital Universitari Germans Trias i Pujol, Badalona, Catalunya, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Revollo","sequence":"additional","affiliation":[{"name":"IrsiCaixa AIDS Research Institute, Badalona, Catalunya, Spain"},{"name":"Department of Infectious Diseases, Hospital Universitari Germans Trias i Pujol, Badalona, Catalunya, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Carrera","sequence":"additional","affiliation":[{"name":"Dermatology Department, Melanoma Group IDIBAPS, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lourdes","family":"Mateu","sequence":"additional","affiliation":[{"name":"IrsiCaixa AIDS Research Institute, Badalona, Catalunya, Spain"},{"name":"Department of Infectious Diseases, Hospital Universitari Germans Trias i Pujol, Badalona, Catalunya, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Fancelli","sequence":"additional","affiliation":[{"name":"Translational Cancer Research Unit, Instituto Oncologico Dr Rosell, Dexeus University Hospital, Barcelona, Spain"},{"name":"Oncology Department, Azienda Ospedaliero Careggi, Firenze, Toscana, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Espinosa","sequence":"additional","affiliation":[{"name":"Oncology Department, Hospital Universitario La Paz, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonaventura","family":"Clotet","sequence":"additional","affiliation":[{"name":"IrsiCaixa AIDS Research Institute, Badalona, Catalunya, Spain"},{"name":"Department of Infectious Diseases, Hospital Universitari Germans Trias i Pujol, Badalona, Catalunya, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Martinez-Picado","sequence":"additional","affiliation":[{"name":"IrsiCaixa AIDS Research Institute, Badalona, Catalunya, Spain"},{"name":"Catalan Institution for Research and Advanced Studies (ICREA), Catalan Institution for Research and Advanced Studies, Barcelona, Catalunya, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Cerezuela","sequence":"additional","affiliation":[{"name":"Oncology Department, Hospital Virgen de la Arrixaca, El Palmar, Murcia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ainara","family":"Soria","sequence":"additional","affiliation":[{"name":"Oncology Department, Hospital Ramon y Cajal, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2476-668X","authenticated-orcid":false,"given":"Ivan","family":"Marquez-Rodas","sequence":"additional","affiliation":[{"name":"Oncology Department, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8846-8959","authenticated-orcid":false,"given":"Mario","family":"Mandala","sequence":"additional","affiliation":[{"name":"Oncology Department, ASST Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Berrocal","sequence":"additional","affiliation":[{"name":"Oncology Department, Consorci Hospital General Universitari de Valencia, Valencia, Comunitat Valenciana, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,3,29]]},"reference":[{"key":"2025100312433245000_9.3.e001664.1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/cid\/ciy012","article-title":"Cancer risk in older persons living with human immunodeficiency virus infection in the United States","volume":"67","author":"Mahale","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2025100312433245000_9.3.e001664.2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129550"},{"key":"2025100312433245000_9.3.e001664.3","doi-asserted-by":"crossref","first-page":"F13","DOI":"10.1097\/QAD.0000000000002298","article-title":"Immunotherapy for cancer in people living with HIV: safety with an efficacy signal from the series in real life experience","volume":"33","author":"Spano","year":"2019","journal-title":"AIDS"},{"key":"2025100312433245000_9.3.e001664.4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00010"},{"key":"2025100312433245000_9.3.e001664.5","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1001\/jamaoncol.2020.0465","article-title":"Assessment of the feasibility and safety of Durvalumab for treatment of solid tumors in patients with HIV-1 infection: the phase 2 DURVAST study","volume":"6","author":"Gonzalez-Cao","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025100312433245000_9.3.e001664.6","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.2244","article-title":"Assessment of the safety of pembrolizumab in patients with HIV and advanced Cancer\u2014A phase 1 study","volume":"5","author":"Uldrick","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100312433245000_9.3.e001664.7","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/jamaoncol.2018.6737","article-title":"Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer","volume":"5","author":"Cook","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100312433245000_9.3.e001664.8","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s12094-018-1981-6","article-title":"Cancer immunotherapy of patients with HIV infection","volume":"21","author":"Gonzalez-Cao","year":"2019","journal-title":"Clin Transl Oncol"},{"key":"2025100312433245000_9.3.e001664.9","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8122089","article-title":"Enhancement of antiviral CD8+ T-cell responses and complete remission of metastatic melanoma in an HIV-1-infected subject treated with pembrolizumab","volume":"8","author":"Blanch-Lombarte","year":"2019","journal-title":"JCM"},{"key":"2025100312433245000_9.3.e001664.10","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.3400","article-title":"Safety of anti-PD-L1 inhibition in HIV-1\u2013Infected patients with Cancer\u2014Reply","volume":"6","author":"Gonzalez-Cao","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025100312433245000_9.3.e001664.11","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0771-1"},{"key":"2025100312433245000_9.3.e001664.12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx696"},{"key":"2025100312433245000_9.3.e001664.13","unstructured":"World Health Organization . Global hepatitis report, 2017. Available: https:\/\/www.who.int\/hepatitis\/publications\/global-hepatitis-report2017\/en\/"},{"key":"2025100312433245000_9.3.e001664.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.10.027"},{"key":"2025100312433245000_9.3.e001664.15","doi-asserted-by":"publisher","DOI":"10.20411\/pai.v2i1.201"},{"key":"2025100312433245000_9.3.e001664.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32111-1"},{"key":"2025100312433245000_9.3.e001664.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31046-2"},{"key":"2025100312433245000_9.3.e001664.18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30351-6"},{"key":"2025100312433245000_9.3.e001664.19","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.4071","article-title":"Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC)","volume":"35","author":"Wainberg","year":"2017","journal-title":"JCO"},{"key":"2025100312433245000_9.3.e001664.20","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.e15675","article-title":"Nivolumab for hepatocellular carcinoma (HCC) in a real-world context","volume":"37","author":"Rao","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025100312433245000_9.3.e001664.21","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0808-5"},{"key":"2025100312433245000_9.3.e001664.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.06.028"},{"key":"2025100312433245000_9.3.e001664.23","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001072"},{"key":"2025100312433245000_9.3.e001664.24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.2571"},{"key":"2025100312433245000_9.3.e001664.25","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1097\/QAD.0000000000001599","article-title":"Hepatitis B reactivation in a long-term nonprogressor due to nivolumab therapy","volume":"31","author":"Lake","year":"2017","journal-title":"AIDS"},{"key":"2025100312433245000_9.3.e001664.26","article-title":"A rare case of Pembrolizumab-Induced reactivation of hepatitis B","volume":"2018","author":"Pandey","year":"2018","journal-title":"Case Rep Oncol Med"},{"key":"2025100312433245000_9.3.e001664.27","unstructured":"WHO global tuberculosis report, 2019. Available: https:\/\/www.who.int\/tb\/publications\/global_report\/en\/"},{"key":"2025100312433245000_9.3.e001664.28","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.11.1014"},{"key":"2025100312433245000_9.3.e001664.29","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0717-7"},{"key":"2025100312433245000_9.3.e001664.30","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00659","article-title":"Tuberculosis infection in a patient treated with nivolumab for non-small cell lung cancer: case report and literature review","volume":"9","author":"van Eeden","year":"2019","journal-title":"Front Oncol"},{"key":"2025100312433245000_9.3.e001664.31","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejca.2020.03.015","article-title":"Immune checkpoint inhibitor use and tuberculosis: a systematic review of the literature","volume":"132","author":"Zaemes","year":"2020","journal-title":"Eur J Cancer"},{"key":"2025100312433245000_9.3.e001664.32","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30674-6"},{"key":"2025100312433245000_9.3.e001664.33","doi-asserted-by":"publisher","DOI":"10.1086\/503917"},{"key":"2025100312433245000_9.3.e001664.34","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv623"},{"key":"2025100312433245000_9.3.e001664.35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806808"},{"key":"2025100312433245000_9.3.e001664.36","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1592"},{"key":"2025100312433245000_9.3.e001664.37","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0585-1"},{"key":"2025100312433245000_9.3.e001664.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.07.005"},{"key":"2025100312433245000_9.3.e001664.39","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ekir.2019.11.015","article-title":"Systematic review of the safety of immune checkpoint inhibitors among kidney transplant patients","volume":"5","author":"Manohar","year":"2020","journal-title":"Kidney Int Rep"},{"key":"2025100312433245000_9.3.e001664.40","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15811"},{"key":"2025100312433245000_9.3.e001664.41","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1080\/0284186X.2018.1479069","article-title":"Graft rejection after immune checkpoint inhibitor therapy in solid organ transplant recipients","volume":"57","author":"Smedman","year":"2018","journal-title":"Acta Oncol"},{"key":"2025100312433245000_9.3.e001664.42","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0171-8"},{"key":"2025100312433245000_9.3.e001664.43","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jdcr.2017.06.005","article-title":"Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade","volume":"3","author":"Miller","year":"2017","journal-title":"JAAD Case Rep"},{"key":"2025100312433245000_9.3.e001664.44","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw130"},{"key":"2025100312433245000_9.3.e001664.45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-02-811174"},{"key":"2025100312433245000_9.3.e001664.46","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.seminoncol.2018.03.003","article-title":"Viable pregnancy in a patient with metastatic melanoma treated with double checkpoint immunotherapy","volume":"45","author":"Burotto","year":"2018","journal-title":"Semin Oncol"},{"key":"2025100312433245000_9.3.e001664.47","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/CMR.0000000000000586","article-title":"Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature","volume":"29","author":"Xu","year":"2019","journal-title":"Melanoma Res"},{"key":"2025100312433245000_9.3.e001664.48","doi-asserted-by":"publisher","DOI":"10.1200\/JGO.17.00175"},{"key":"2025100312433245000_9.3.e001664.49","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3389\/fmed.2020.00137","article-title":"Efficacy and toxicity of immune -Checkpoint inhibitors in patients with preexisting autoimmune disorders","volume":"7","author":"Coureau","year":"2020","journal-title":"Front Med"},{"key":"2025100312433245000_9.3.e001664.50","doi-asserted-by":"publisher","DOI":"10.7326\/M17-2073"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-001664","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:43:39Z","timestamp":1759520619000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-001664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,29]]},"published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1136\/jitc-2020-001664"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-001664","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3]]}}}